Item Type: | Article |
---|---|
Title: | In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment |
Creators Name: | Naundorf, S., Preithner, S., Mayer, P., Lippold, S., Wolf, A., Hanakam, F., Fichtner, I., Kufer, P., Raum, T., Riethmueller, G., Baeuerle, P.A. and Dreier, T. |
Abstract: | In our study, a novel, fully human, recombinant monoclonal antibody of the IgG1 isotype, called MT201, was characterized for its binding properties, complement-dependent (CDC) and antibody-dependent cellular cytotoxicity (ADCC), as well as for its in vivo antitumor activity in a nude mouse model. MT201 was found to bind its target, the epithelial cell adhesion molecule (Ep-CAM; also called 17-1A antigen, KSA, EGP-2, GA733-2), with low affinity in a range similar to that of the clinically validated, murine monoclonal IgG2a antibody edrecolomab (Panorex®). MT201 exhibited Ep-CAM-specific CDC with a potency similar to that of edrecolomab. However, the efficacy of ADCC of MT201, as mediated by human immune effector cells, was by 2 orders of magnitude higher than that of edrecolomab. Addition of human serum reduced the ADCC of MT201 while it essentially abolished ADCC of edrecolomab within the concentration range tested. In a nude mouse xenograft model, growth of tumors derived from the human colon carcinoma line HT-29 was significantly and comparably suppressed by MT201 and edrecolomab. The fully human nature and the improved ADCC of MT201 with human effector cells will make MT201 a promising candidate for the clinical development of a novel pan-carcinoma antibody that is superior to edrecolomab. |
Keywords: | Ep-CAM, Edrecolomab, Monoclonal Antibody, Animals, Cricetinae, Mice |
Source: | International Journal of Cancer |
ISSN: | 0020-7136 |
Publisher: | Wiley |
Volume: | 100 |
Number: | 1 |
Page Range: | 101-110 |
Date: | 1 July 2002 |
Official Publication: | https://doi.org/10.1002/ijc.10443 |
PubMed: | View item in PubMed |
Repository Staff Only: item control page